ストックスクリーナーアプリを入手
19.98
5.75%
-1.22
アフターアワーズ：
20.00
0.02
+0.10%
前日終値:
$21.20
開ける：
$20.72
24時間の取引高:
4.13M
Relative Volume:
1.25
時価総額：
$5.62B
収益：
$426.45M
当期純損益:
$197.67M
株価収益率:
24.37
EPS:
0.82
ネットキャッシュフロー:
$110.10M
1週間 パフォーマンス:
-15.05%
1か月 パフォーマンス:
+3.04%
6か月 パフォーマンス:
-11.67%
1年 パフォーマンス:
+188.31%
1日の値動き範囲:
$19.86
$21.48
1週間の範囲:
$18.75
$24.17
52週間の値動き範囲:
$7.96
$25.67
Adma Biologics Inc Stock (ADMA) Company Profile
ADMA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
19.98 | 5.62B | 426.45M | 197.67M | 110.10M | 0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-07-19 | 再開されました | Raymond James | Strong Buy |
| 2022-10-13 | 開始されました | Mizuho | Buy |
| 2021-11-11 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2021-11-09 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-06-04 | 開始されました | Jefferies | Buy |
| 2019-04-15 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-02-07 | 再開されました | H.C. Wainwright | Buy |
| 2017-12-11 | 繰り返されました | Maxim Group | Buy |
| 2017-11-14 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2017-01-23 | アップグレード | Maxim Group | Hold → Buy |
| 2016-08-01 | ダウングレード | Maxim Group | Buy → Hold |
| 2016-07-25 | 繰り返されました | Maxim Group | Buy |
| 2015-05-13 | 繰り返されました | Maxim Group | Buy |
| 2014-12-08 | 開始されました | Oppenheimer | Outperform |
| 2014-12-01 | 繰り返されました | Maxim Group | Buy |
すべてを表示
Adma Biologics Inc (ADMA) 最新ニュース
PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates - Zacks Investment Research
Revenue Gains, Bold Guidance Lift ADMA Shares - FXEmpire
ADMA Biologics: Ready For More Growth Despite Q1 Earnings Miss (NASDAQ:ADMA) - Seeking Alpha
ADMA Biologics Reports Strong Growth and Strategic Advances - TipRanks
ADMA Biologics (ADMA) Receives Price Target Upgrade from Raymond James | ADMA Stock News - GuruFocus
ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock? - TradingView
Why IBD 50's No. 2 Stock, ADMA Biologics, Just Plummeted By Double Digits - MSN
Crude Oil Gains Over 2%; US Foods Posts Downbeat Earnings - Benzinga
Raymond James Increases Price Target for ADMA Biologics | ADMA Stock News - GuruFocus
ADMA Biologics, Inc. (NASDAQ:ADMA) Q1 2025 Earnings Call Transcript - Insider Monkey
ADMA Biologics Inc (ADMA) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
ADMA Biologics Inc (ADMA) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Initiatives Propel Future Outlook - GuruFocus
Adma Biologics: Q1 Earnings Snapshot - New Haven Register
ADMA Biologics Reports Strong Q1 2025 Financial Growth - TipRanks
ADMA Biologics Inc earnings missed by $0.01, revenue topped estimates - Investing.com Nigeria
ADMA Biologics Q1 2025 Earnings: EPS of $0.16 Meets Estimates, R - GuruFocus
ADMA Biologics Q1 Earnings, Revenue Rise; Shares Fall After Hours - marketscreener.com
Earnings call transcript: ADMA Biologics Q1 2025 sees revenue beat, mixed stock reaction - Investing.com
Adma Biologics (ADMA) Misses Q1 Earnings and Revenue Estimates - Yahoo Finance
ADMA BIOLOGICS, INC. SEC 10-Q Report - TradingView
ADMA Biologics (ADMA) Misses Revenue Estimates Despite Strong Growth - GuruFocus
ADMA Biologics Announces $500M Share Repurchase Program - TipRanks
ADMA Biologics Q1 2025 Earnings: EPS of $0.16 Meets Estimates, Revenue of $114.8M Misses Expectations - GuruFocus
Earnings Flash (ADMA) Adma Biologics Posts Q1 Diluted EPS $0.11, vs. FactSet Est of $0.15 - marketscreener.com
ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
ADMA Options Activity Suggests Anticipated Post-Earnings Volatility | ADMA Stock News - GuruFocus
Adma Biologics options imply 10.9% move in share price post-earnings - TipRanks
3 Mid-Cap Medical Stocks Outperforming the Market - Investing.com
Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down - Zacks Investment Research
ADMA Biologics Earnings Preview - Nasdaq
RXRX Stock Down 17% as Q1 Earnings & Revenues Miss Estimates - Zacks Investment Research
Take the Zacks Approach to Beat the Markets: ADMA Biologics, Limbach, Quest Diagnostics in Focus - MSN
(ADMA) Technical Data - news.stocktradersdaily.com
Should ADMA Biologics Stock Be in Your Portfolio Pre-Q1 Earnings? - MSN
Adma Biologics (ADMA) Increases Yet Falls Behind Market: What Investors Need to Know - Yahoo Finance
Investors Heavily Search ADMA Biologics Inc (ADMA): Here is What You Need to Know - MSN
Bausch Health Q1 Earnings and Revenues Miss Estimates, Stock Down - The Globe and Mail
Has ADMA Biologics (ADMA) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why - Yahoo Finance
The Zacks Analyst Blog Highlights ADMA, FirstCash, Stride, Life Time Group and National Fuel Gas - The Globe and Mail
Why ADMA Biologics, Inc. (ADMA) Surged on Monday - MSN
These 5 Buy-Ranked Mid-Cap Stocks Are Flying High Year to Date - The Globe and Mail
ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025 - The Manila Times
Adma Biologics (ADMA) Stock Slides as Market Rises: Facts to Know Before You Trade - MSN
ADMA Biologics (ADMA) Achieves Key FDA Approval for Production B - GuruFocus
ADMA Biologics (ADMA) Attracts Hedge Fund Attention Amid Takeover Speculation - GuruFocus
Adma Biologics Inc (ADMA) 財務データ
収益
当期純利益
現金流量
EPS
0.84%
0.15%
大文字化:
|
ボリューム (24 時間):